MRS

References

• Kalra S, Arnold DL, Cashman NR. Biological markers in the diagnosis and treatment of ALS. J Neurol Sci 1999; 165 (Suppl 1): S27–32.
   Google Scholar
• Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45(1): 37–45.
   PubMed Web of Science ®Google Scholar
• Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immuno- histochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2(3): 131–134.
   PubMedGoogle Scholar
• Battistuta J, Bjartmar C, Trapp BD. Post mortem degradation of N-acetyl aspartate and N-acetyl aspartylglutamate: an HPLC analysis of different rat CNS regions. Neurochem Res 2001; 26(6): 695–702.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44(10): 1933–1938.
   PubMed Web of Science ®Google Scholar
• Jones AP, Gunawardena WJ, Coutinho CM, Gatt JA, Shaw IC, Mitchell JD. Preliminary results of proton magnetic resonance- spectroscopy in motor neuron disease (amytrophic lateral sclerosis). J Neurol Sci 1995; 129 (suppl): 85–89.
   Google Scholar
• Giroud M, Walker P, Bernard D et al. Reduced brain N-acetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Neurological Research 1996; 18(3): 241–243.
   Google Scholar
• Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectro- scopy. Neurology 1997; 48(4): 878–881.
   PubMed Web of Science ®Google Scholar
• Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998; 50(6): 1800– 1805.
   PubMed Web of Science ®Google Scholar
• Block W, Karitzky J, Traber F et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998; 55(7): 931–936.
   Google Scholar
• Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C. A prospective study of cognitive impairment in ALS. Neurology 1999; 53(8): 1665–1670.
   PubMed Web of Science ®Google Scholar
• Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP. Motor neuron diseases: comparison of single- voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212(3): 763– 769.
   PubMed Web of Science ®Google Scholar
• Bowen BC, Pattany PM, Bradley WG et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 647–658.
   Google Scholar
• Pohl C, Block W, Karitzky J et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyo- trophic lateral sclerosis. Arch Neurol 2001; 58(5): 729–735.
   Google Scholar
• Vielhaber S, Kaufmann J, Kanowski M et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001; 172(2): 377–382.
   Google Scholar
• Sarchielli P, Pelliccioli GP, Tarducci R et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001; 43(3): 189–197.
   Google Scholar
• Schuff N, Rooney WD, Miller R et al. Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med 2001; 45(3): 513–516.
   Google Scholar
• Abe K, Takanashi M, Watanabe Y et al. Decrease in N- acetylaspartate/creatine –ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001; 43(7): 537–541.
   Google Scholar
• Kenn W, Ochs G, Pabst TA, Hahn D. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 2001; 11(3): 293–297.
   PubMed Web of Science ®Google Scholar
• Suhy J, Miller RG, Rule R et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI. Neurology 2002; 58: 773–779.
   Google Scholar
• Hanstock CC, Cwik VA, Martin WR. Reduction in metabolite transverse relation times in amyotrophic lateral sclerosis. J Neurol Sci 2002; 198: 37–41.
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. ALS and Other Motor Neuron Disorders. (In press.)
   Google Scholar
• Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Magnetic resonance spectroscopic imaging reveals lack of improvement in neuronal integrity with gabapentin therapy. American Journal of Neuroradiology. (In press.)
   Google Scholar
• Cwik VA, Hanstock CC, Allen PS, Martin WR. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998; 50(1): 72–77.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Majors AW, Mitsumoto H, Nelson DR, Ng TC. 1H-MRS evidence of neurodegeneration and excess glutamate- zglutamine in ALS medulla. Neurology 1999; 53(1): 71–79.
   PubMed Web of Science ®Google Scholar
• Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol 2003; 24(3): 476–480.
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold D. A prospective, randomized, placebo controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4(1): 22–26.
   PubMed Web of Science ®Google Scholar
• Parent A. Carpenter’s Human Neuroanatomy. 9th ed. Baltimore: Williams and Wilkins, 1996.
   Google Scholar
• Martin JE, Swash M. The pathology of motor neuron disease. In: Leigh PN, Swash M, editors. Motor Neuron Disease. Biology and Management. London: Springer-Verlag, 1995: 93–118.
   Google Scholar
• Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9(8): 1757– 1761.
   PubMed Web of Science ®Google Scholar
• Matthews PM, Cianfaglia L, McLaurin J et al. Demonstration of reversible decreases in N-acetylaspartate (NAA) in a neuronal cell line: NAA decreases as a marker of sublethal neuronal dysfunction. Proceedings of the Society of Magnetic Resonance and the European Society for Magnetic Resonance in Medicine and Biology 1, 147. 1995. (Abstract).
   Google Scholar
• Demougeot C, Garnier P, Mossiat C et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001; 77(2): 408–415.
   Google Scholar
• Gasparovic C, Arfai N, Smid N, Feeney DM. Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury. J Neurotrauma 2001; 18(3): 241–246.
   PubMed Web of Science ®Google Scholar
• Jenkins BG, Klivenyi P, Kustermann E et al. Non-linear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington’s disease mice. J Neurochem 2000; 74(5): 2108–2119.
   Google Scholar
• De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. MRM 1995; 34(5): 721–727.
   PubMed Web of Science ®Google Scholar
• Uno M, Ueda S, Hondo H, Matsumoto K, Harada M. Effectiveness of revascularization surgery evaluated by proton magnetic resonance spectroscopy and single photon emission computed tomography. Neurologia Medico-Chirurgica 1996; 36(8): 560–566.
   PubMedGoogle Scholar
• Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectro- scopic imaging. Neurology 1997; 49(6): 1525–1533.
   Google Scholar
• Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localized magnetic resonance spectroscopy. Lancet 1995; 345(8941): 60–61.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jenkins BG, Dedeoglu A et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001; 77(2): 383–390.
   Google Scholar